|
Cornell Chronicles: Posted on Tuesday, August 30, 2011 4:05 PM
'Smart' nanoparticles identify, target and kill cancer cells
Another weapon in the arsenal against cancer has been invented at Cornell: nanoparticles that identify, target and kill specific cancer cells while leaving healthy cells alone.
Led by Carl Batt, the Liberty Hyde Bailey Professor of Food Science, the researchers synthesized nanoparticles -- shaped something like a dumbbell -- made of gold sandwiched between two pieces of iron oxide. They then attached antibodies that target a molecule found only in colorectal cancer cells to the particles. |
|
|
National Breast Cancer Foundation, inc.: Posted on Monday, August 29, 2011 9:57 PM
Breast cancer type is categorized by whether it begins in the ducts or lobules, the organs responsible for breast milk production. Understanding the specific type of breast cancer can help you ask better questions and work with your physicians to get the best breast cancer treatments.
Ductal Carcinoma In-Situ (DCIS)
Infiltrating Ductal Carcinoma (IDC)
Medullary Carcinoma
Infiltrating Lobular Carcinoma (ILC)
Tubular Carcinoma
Mucinous Carcinoma (Colloid)
Inflammatory Breast Cancer (IBC) For more information on the types and |
|
|
NCI: Posted on Monday, August 29, 2011 11:37 AM
Researchers in Japan have developed an experimental blood test that may help identify patients with colorectal cancer who have an aggressive form of the disease and could benefit from additional therapy after surgery.The test screens the blood for tumor cells that have three molecular markers, including a marker for the protein CD133. This marker is found on some cells that have the properties of stem cells, such as the ability to self renew. Without CD133, the test results were not informative, suggesting to the researchers the importance of this cancer stem cell marker. |
|
|
NCI: Posted on Sunday, August 28, 2011 9:04 PM
Eribulin Improves Survival of Women with Metastatic Breast Cancer
Treatment with eribulin (Halaven) improved overall survival in women with metastatic breast cancer whose disease progressed despite multiple rounds of prior chemotherapy, according to the results of a phase III clinical trial called EMBRACE. Based on these findings, the FDA approved eribulin last November for women with metastatic disease who have already undergone at least two previous chemotherapy regimens. |
|
|
NCI: Posted on Friday, August 26, 2011 12:53 PM
Among women who survive breast cancer, the most frequent new cancer occurs in the opposite, or contralateral, breast. Since 1985, a new study reports, the incidence rate of contralateral breast cancer has declined steadily—at a pace of more than 3 percent per year. Although the causes of this trend are not known, the decline occurred as drugs such as tamoxifen were coming into widespread use to help prevent a recurrence of the disease, researchers reported online in the |
|
|
NCI: Posted on Friday, August 26, 2011 12:43 PM
Researchers have identified a protein that may play a critical role in preventing some tumors from responding to the breast cancer drug trastuzumab (Herceptin). The researchers also showed, in preclinical experiments, that it may be possible to overcome this resistance by combining trastuzumab with a drug to inhibit the protein, c-SRC. The findings appeared online in Nature Medicine on March 13.Multiple mechanisms of resistance associated with trastuzumab have been identified, but there are no effective methods for overcoming this resistance. |
|
|
NCI: Posted on Thursday, August 25, 2011 4:30 PM
Many male survivors of childhood cancer have long been thought to be sterile and, therefore, incapable of conceiving a child. But a new study suggests that conception and fatherhood may be possible for a substantial number of these men, through the use of a surgical procedure to retrieve healthy sperm combined with a form of in vitro fertilization (IVF).In the retrospective study, researchers from New York-Presbyterian Hospital/Weill Cornell Medical Center showed that nearly 2 decades after cancer treatment, healthy sperm could be retrieved from the testicles of more than one-third of male cancer survivors who had a condition in which no viable sperm was detectable in their semen. |
|
|
NCI: Posted on Tuesday, August 23, 2011 8:36 PM
Dr. Neeraj Arora was a 25-year-old graduate student when he was diagnosed with non-Hodgkin lymphoma (NHL). His oncologist recommended aggressive chemotherapy and radiation, beginning immediately, to stem the rapid growth of the cancer.One day, waiting in the doctor’s office for his next round of chemotherapy, he happened to pick up a booklet about NHL treatment. Infertility, he read, was a common side effect of the regimen he was receiving.“My doctors somehow forgot to mention that,” Dr. |
|
|
"MEMOIRS OF CANCER' BY DINA NWAOKAI-BEECHAM: Posted on Tuesday, August 23, 2011 5:00 PM
"Triple negative breast cancers are those which are not receptive to ENDOCRINE treatments, because they do not express the estrogen, progesterone or HER-2 receptors. As a result, Triple negative breast cancers can not be treated with anti-HER-2 therapy because they do not express the her-2 receptor. Most women with breast cancer fall into the estrogen/progesterone/HER-2 positive category and that affords the oncologist a wider selectionn of chemotherapy to chose from in treating their cancer. |
|
|
Posted on Monday, August 22, 2011 8:31 PM
JOIN US FOR A FREE WEBINAR!Surgery for Pancreatic CancerMonday, August 29, 2011 10:00 AM - 11:00 AM PDT Space is limited.Reserve your Webinar seat now at: https://www2.gotomeeting.com/register/166707930 This webinar will highlight common surgical procedures for treating pancreatic cancer as well as advances in the field. This session will be presented by Mark Talamonti, MD. After registering you will receive a confirmation email containing information about joining the Webinar. System Requirements |
|
